Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 7/20 | 0.39 |
| ▸ | ACHE | P22303 | 7/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1823346 | 0.90 | BCHE (0.40) | MTNR1AMTNR1BKMT2ASMN1; SMN2FAAH | |
| SCHEMBL1827195 | 0.90 | SLC15A1 (0.46) | MTNR1AMTNR1BKMT2ASMN1; SMN2FAAH | |
| SCHEMBL3575911 | 0.90 | MTNR1A (0.41) | MTNR1AMTNR1BKMT2ASMN1; SMN2KCNA5 | |
| SCHEMBL1824554 | 0.90 | F10 (0.42) | MTNR1AMTNR1BKMT2ASMN1; SMN2FAAH | |
| SCHEMBL1823860 | 0.89 | CA2 (0.41) | MTNR1AMTNR1BKMT2ASMN1; SMN2FAAH | |
| SCHEMBL1824709 | 0.88 | LTA4H (0.43) | KMT2AKCNA5ACHELTA4HMEN1 | |
| SCHEMBL1826085 | 0.86 | PLAU (0.41) | MTNR1AMTNR1BKMT2ASMN1; SMN2 | |
| SCHEMBL1825670 | 0.85 | KMT2A (0.43) | KMT2ASMN1; SMN2KCNA5FAAHACHE | |
| SCHEMBL1826340 | 0.84 | LTA4H (0.46) | MTNR1AMTNR1BKMT2ASMN1; SMN2FAAH | |
| SCHEMBL1823045 | 0.80 | BCHE (0.39) | MTNR1AMTNR1BKMT2ASMN1; SMN2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2161254-B1 | Intermediate for preparing a biaryl compound | SUMITOMO CHEMICAL CO (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-1481967-B1 | PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-7714157-B2 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-2161254-A1 | Intermediate for preparing a biaryl compound | Sumitomo Chemical Company, Limited (JP) | 2010-03-10 | — | — | EP | disclosed |
| US-20070270603-A1 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-11-22 | — | — | US | disclosed |
| US-7271280-B2 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-18 | — | — | US | disclosed |
| EP-1481967-A1 | PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS | Sumitomo Chemical Company, Limited (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040158093-A1 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158093-A1 | Process for preparing a biaryl compound | CYP1B1, REL, CYP2F1 | MTNR1A 2715/4885MTNR1B 1718/4885KMT2A 1068/4885 |
| US-20070270603-A1 | Process for preparing a biaryl compound | CYP4A11, CYP4B1, CYP51A1 | MTNR1A 3986/4885MTNR1B 3105/4885KMT2A 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.